KyungDong Pharm Co., Ltd. has launched Esokabojeong, a ‘PPI + antacid’ combination drug for gastroesophageal reflux disease.
Esokabo Tablet, released on the 1st, is a combination drug that combines precipitated calcium carbonate, an antacid ingredient, with the single agent esomeprazole, which is used to treat gastroesophageal reflux disease, and is a new product launched through joint development by KyungDong Pharm, Yuhan Corporation, and Green Cross.
In a clinical trial conducted over 4 weeks, Esokabojeong showed a similar effect on suppressing gastric acid secretion as the single agent esomeprazole, and the time to reach the highest blood concentration (Tmax) was 30 minutes, which is about 3 times faster than the single agent.
PPI (Proton Pump Inhibitor) agents such as esomeprazole are sensitive to acidic environments due to the nature of their ingredients and are easily decomposed when exposed to the stomach. To complement these characteristics, existing esomeprazole single agents generally use an enteric coating agent that dissolves in the intestines, but this has the disadvantage of delaying the drug effect onset time.
Esokabojeong neutralizes the acidic environment in the stomach by combining the antacid calcium carbonate component instead of enteric coating, which delays the drug effect onset time, and quickly releases the esomeprazole component, shortening the time to reach the highest blood concentration.
An official from KyungDong Pharm said, "Esokabojeong has a differentiated feature of faster drug efficacy compared to PPI single agents. In addition, the dosage size is smaller than existing PPI combination products, increasing patients' medication convenience. This is expected to be helpful in treating patients suffering from gastroesophageal reflux disease."
♠ Product Information ♠
|
Product name |
Esoka Correction 20/600mg Esoka Correction 40/600mg |
|
Ingredient content |
Esokabojeong 20/600mg: esomeprazole 22.3mg / precipitated calcium carbonate 600mg Esokabojeong 40/600mg: esomeprazole 44.5mg / precipitated calcium carbonate 600mg |
|
Gender |
Esokabojeong 20/600mg: Yellow oblong film-coated tablet Esokabojeong 40/600mg: Pink, oblong, film-coated tablet |
|
Indications |
Gastroesophageal reflux disease (GERD)
- Treatment of erosive reflux esophagitis
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis
- Treatment for symptoms of gastroesophageal reflux disease without esophagitis |
|
Dosage and usage |
Take this medication on an empty stomach at least 1 hour before a meal.
Gastroesophageal reflux disease (GERD)
- Treatment of erosive reflux esophagitis: 1 40mg tablet once a day
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 1 20mg tablet once a day
- Treatment for symptoms of gastroesophageal reflux disease without esophagitis: 1 20mg tablet once a day ※ Please refer to the manual for further details. |
|
How to save |
Airtight container, stored at room temperature (1~30℃) |
|
Packaging unit |
28 tablets/bottle |
|
Insurance claim code |
Esoka Correction 20/600mg: 648104610 Esoka Correction 40/600mg: 648104620 |
|
Standard drug price |
Esoka Correction 20/600mg: 797 won/tablet Esokabojeong 40/600mg: KRW 1,111/tablet |